MedPath

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

Phase 3
Terminated
Conditions
Recurrent C. Difficile Infection
Interventions
Biological: CP101
Other: Placebo
Registration Number
NCT05153499
Lead Sponsor
Finch Research and Development LLC.
Brief Summary

This is a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4). This Phase 3 trial will be conducted in 2 parts: a randomized, double-blind, placebo-controlled trial arm and an optional open-label treatment arm. After completing standard-of-care (SOC) CDI antibiotics for their most recent CDI recurrence, patients who meet all eligibility requirements will be randomized in a 2:1 ratio to receive either CP101 or placebo. Patients will be evaluated for CDI recurrence and safety follow-up through Week 8, the primary endpoint, as well as through Week 24. Patients who qualify may enroll into the optional open label arm if they experience CDI recurrence through week 8.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
19
Inclusion Criteria
  • Ability to provide written informed consent

  • Men or women over 18 years of age or older

  • Current diagnosis of a recurrence of non-severe, non-complicated CDI

  • Subject has a clinical response to standard-of-care CDI antibiotics for the most recent CDI episode

  • History of recurrent CDI defined as:

    • ≥ 3 episodes of CDI, with 2 episodes occurring within the previous 6 months (inclusive of the current episode); OR
    • Patients with a history of 2 episodes of CDI occurring within the previous 6 months (inclusive of the current episode) may be eligible if 65 years of age or older.
  • For the Qualifying CDI episode, the following criteria must be satisfied:

    • History of diarrhea (> 3 unformed stools per day) for 2 or more consecutive days that is clinically consistent with CDI. AND
    • Documented positive stool test by local laboratory for toxigenic C. difficile (toxin enzyme immunoassay [EIA] or polymerase chain reaction [PCR]-based testing) for the current CDI episode and within 45 days prior to Randomization. AND
    • Received a course of SOC CDI antibiotics for the most recent CDI episode (for 10 to 21 days, with exact duration, antibiotic type, and dose at the discretion of the Investigator). AND
    • Demonstrated an adequate clinical response, defined as ≤ 3 unformed stools in 24 hours for 2 or more consecutive days during SOC CDI antibiotics prior to Randomization.
Exclusion Criteria
  • Known stool sample testing positive for enteric pathogen(s) (e.g., Salmonella, Shigella, diarrhoeagenic E. coli, Campylobacter, Giardia) within 28 days prior to Screening
  • Pregnant, breast-feeding, or planning to become pregnant during the trial
  • Historical or current diagnosis of inflammatory bowel disease
  • Recent diagnosis (<6 months prior to screening) of diarrhea-predominant irritable bowel syndrome (post-infection or non-related to an enteric infection)
  • Initiation of any systemic cancer treatment (e.g., chemotherapy, radiotherapy, biologic, immunotherapy, others) for active malignancy
  • Major intra-abdominal surgery (e.g., bowel resection)
  • Known primary or secondary immunodeficiency

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CP101CP101-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
Sustained Clinical Cure Through Week 8Week 8

No data displayed because Outcome Measure has zero participants analyzed.

Secondary Outcome Measures
NameTimeMethod
Sustained Clinical Cure Through Week 24Week 24

No data displayed because Outcome Measure has zero participants analyzed.

CDI Recurrence Through Week 24 as Evidenced by Positive Toxin EIA or Positive Toxigenic CultureWeek 24

No data displayed because Outcome Measure has zero participants analyzed.

Trial Locations

Locations (67)

Chevy Chase Clinical Research

🇺🇸

Chevy Chase, Maryland, United States

NorthShore University HealthSystem

🇺🇸

Evanston, Illinois, United States

Brody School of Medicine at ECU

🇺🇸

Greenville, North Carolina, United States

1960 Family Practice P.A.

🇺🇸

Houston, Texas, United States

Pinehurst Medical Clinic Inc

🇺🇸

Pinehurst, North Carolina, United States

TruCare Internal Medicine & Infectious Diseases

🇺🇸

DuBois, Pennsylvania, United States

Vancouver Island Health Authority

🇨🇦

Victoria, British Columbia, Canada

MedPharmics LLC

🇺🇸

Gulfport, Mississippi, United States

Medical Research Center of Connecticut LLC

🇺🇸

Hamden, Connecticut, United States

ENCORE Borland-Groover Clinical Research

🇺🇸

Jacksonville, Florida, United States

Snake River Research, PLLC

🇺🇸

Idaho Falls, Idaho, United States

Dalhousie University

🇨🇦

Halifax, Nova Scotia, Canada

George Washington University School of Medicine and Health

🇺🇸

Washington, District of Columbia, United States

Brigham and Womens Hospital

🇺🇸

Boston, Massachusetts, United States

Theia Clinical Research, LLC

🇺🇸

Saint Petersburg, Florida, United States

Mercury Street Medical Group

🇺🇸

Butte, Montana, United States

Gastroenterology Group of Naples

🇺🇸

Naples, Florida, United States

Metro Infectious Disease Consultants

🇺🇸

Burr Ridge, Illinois, United States

NYU Langone Medical Center

🇺🇸

New York, New York, United States

Regional GI

🇺🇸

Lancaster, Pennsylvania, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Guthrie Clinic

🇺🇸

Sayre, Pennsylvania, United States

Mayo Clinic Jacksonville

🇺🇸

Jacksonville, Florida, United States

Bridgeport Hospital

🇺🇸

Bridgeport, Connecticut, United States

Hartford Hospital

🇺🇸

Hartford, Connecticut, United States

CARe Clinic

🇨🇦

Red Deer, Alberta, Canada

Main Street Physicians Care

🇺🇸

Loris, South Carolina, United States

Christiana Care Health System

🇺🇸

Newark, Delaware, United States

Kelsey Seybold Clinic

🇺🇸

Houston, Texas, United States

University of Calgary - Calgary Health Region

🇨🇦

Calgary, Alberta, Canada

Infectious Diseases Associates of Central Virginia

🇺🇸

Lynchburg, Virginia, United States

Yazdan Medical Corporation

🇨🇦

Vancouver, British Columbia, Canada

Saint Joseph's Health Care London

🇨🇦

London, Ontario, Canada

San Marcus Research Clinic Inc

🇺🇸

Miami, Florida, United States

Gastro Health LLC

🇺🇸

Cincinnati, Ohio, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

University of Colorado School of Medicine

🇺🇸

Aurora, Colorado, United States

Sylvester Comprehensive Cancer Center

🇺🇸

Miami, Florida, United States

Reliant Medical Research

🇺🇸

Miami, Florida, United States

St Joseph's Comprehensive Research Institute

🇺🇸

Tampa, Florida, United States

Southern Star Research Institute LLC

🇺🇸

San Antonio, Texas, United States

University of Utah

🇺🇸

Salt Lake City, Utah, United States

Wake Forest Baptist Medical Center

🇺🇸

Winston-Salem, North Carolina, United States

Stanford Healthcare

🇺🇸

Stanford, California, United States

Facey Medical Foundation

🇺🇸

Mission Hills, California, United States

Kaiser Permanente Division of Research

🇺🇸

Oakland, California, United States

UCSF

🇺🇸

San Francisco, California, United States

Guardian Angel Research

🇺🇸

Tampa, Florida, United States

Emory University Hospital Midtown

🇺🇸

Atlanta, Georgia, United States

Iowa Clinic

🇺🇸

Des Moines, Iowa, United States

Loyola University Medical Center

🇺🇸

Maywood, Illinois, United States

Henry Ford Health System

🇺🇸

Novi, Michigan, United States

William Beaumont Hospital

🇺🇸

Farmington Hills, Michigan, United States

St. Charles Clinical Research, LLC

🇺🇸

Weldon Spring, Missouri, United States

North Shore University Hospital-(Manhasset)

🇺🇸

Manhasset, New York, United States

Weill Cornell Medicine

🇺🇸

New York, New York, United States

Mount Sinai Hospital

🇺🇸

New York, New York, United States

Digiovanna Institute For Medical Education and Research

🇺🇸

North Massapequa, New York, United States

Central New York Research Corporation

🇺🇸

Syracuse, New York, United States

Women's Medicine Collaborative

🇺🇸

Providence, Rhode Island, United States

Digestive Health Associates of Texas, PA

🇺🇸

Carrollton, Texas, United States

University Health Network

🇨🇦

Toronto, Ontario, Canada

Ochsner Clinic Foundation

🇺🇸

New Orleans, Louisiana, United States

University of North Carolina at Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

Lowcountry Infectious Diseases PA

🇺🇸

Charleston, South Carolina, United States

University of Florida Health

🇺🇸

Gainesville, Florida, United States

Montefiore Medical Center

🇺🇸

Bronx, New York, United States

© Copyright 2025. All Rights Reserved by MedPath